/images/ppid_59c68470-image-176906259731194097.webp)
In a press release filed with the exchanges, Zydus Life said it has introduced the biosimilar under the brand name Tishtha™, which will be used to treat multiple cancers. The company said the therapy will be available at nearly one-fourth the cost of the reference drug, significantly lowering the treatment burden for patients.
Tishtha™ will be sold in two dosages, 100 mg priced at ₹28,950 and 40 mg priced at ₹13,950. According to Zydus, the pricing and dual-strength offering will help oncologists optimise dosing while minimising drug wastage, a key factor in improving the economics of immunotherapy.
According to Zydus' estimates, the treatment could benefit more than five lakh patients in India by improving affordability and widening access to immuno-oncology therapies.
Commenting on the launch, Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences, said, “At Zydus, we believe every patient deserves timely access to affordable, advanced cancer care. With the launch of Tishtha™, we are expanding access to Immuno-Oncology through a patient-centric therapy.”
The pharma major highlighted that access to modern cancer treatment hinges on consistency, affordability and reach. As Tishtha™ has been developed and manufactured in India, the company said it ensures reliable and sustained availability for patients who require uninterrupted therapy over multiple treatment cycles.
The launch further strengthens Zydus’ presence in advanced biologics and immuno-oncology, aligning with its broader strategy to expand access to high-quality biosimilar therapies in India and other markets.
The company is also in talks to acquire US biopharma firm Ardelyx , sources told CNBC-TV18 on Tuesday, adding that the company is looking at raising funds via qualified institutional placement (QIP) to part-fund the acquisition.
Earlier this month, Zydus Lifesciences' US subsidiary Sentynl Therapeutics Inc. received approval from the USFDA for ZYCUBO® (copper histidinate), making it the first and only approved therapy for Menkes disease in the United States.
Following the announcement, shares of the company were trading 1.16% up at ₹886.45 as of 10.36 am. The stock has dropped 3.46% in the past one month.
